Myeloproliferative neoplasms (MPNs) are diseases caused by mutations in the
haematopoietic stem cell (HSC) compartment. Most MPN patients have a common acquired …

Signals emanating from the bone marrow microenvironment, such as stromal cells, are
thought to support the survival and proliferation of the malignant cells in patients with …

Myeloproliferative neoplasms (MPNs) arise in the hematopoietic stem cell (HSC)
compartment as a result of the acquisition of somatic mutations in a single HSC that provides …

The majority of patients with myeloproliferative neoplasms (MPNs) carry a somatic JAK2-
V617F mutation. Because additional mutations can precede JAK2-V617F, it is questioned …

Abstract The JAK2V617F somatic point mutation has been described in patients with
myeloproliferative disorders (MPDs). Despite this progress, it remains unknown how a single …

Recent descriptions of significant heterogeneity in normal stem cells and cancers have
altered our understanding of tumorigenesis, emphasizing the need to understand how …

We report a Jak2V617F knockin mouse myeloproliferative neoplasm (MPN) model
resembling human polycythemia vera (PV). The MPN is serially transplantable and we …

Proinflammatory cytokines such as TNFα are elevated in patients with myeloproliferative
neoplasms (MPN), but their contribution to disease pathogenesis is unknown. Here we …

The implications of stem cell heterogeneity for disease pathogenesis and therapy are poorly
defined. JAK2V617F+ myeloproliferative neoplasms (MPNs), harboring the same mutation …

Purpose: The myeloproliferative neoplasms (MPN), including polycythemia vera, essential
thrombocythemia, and primary myelofibrosis, are characterized by the expansion of the …